AU2001255475B2 - Method of reducing side effects of chemotherapy in cancer patients - Google Patents

Method of reducing side effects of chemotherapy in cancer patients Download PDF

Info

Publication number
AU2001255475B2
AU2001255475B2 AU2001255475A AU2001255475A AU2001255475B2 AU 2001255475 B2 AU2001255475 B2 AU 2001255475B2 AU 2001255475 A AU2001255475 A AU 2001255475A AU 2001255475 A AU2001255475 A AU 2001255475A AU 2001255475 B2 AU2001255475 B2 AU 2001255475B2
Authority
AU
Australia
Prior art keywords
administration
administered
hcl
chemotherapy agent
chemotherapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2001255475A
Other languages
English (en)
Other versions
AU2001255475A1 (en
AU2001255475A2 (en
Inventor
Maggie Jie Quan
Alfred R. Rudolph
Vincent Chung-Yin Tam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sciclone Pharmaceuticals LLC
Original Assignee
Sciclone Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals LLC filed Critical Sciclone Pharmaceuticals LLC
Publication of AU2001255475A1 publication Critical patent/AU2001255475A1/en
Publication of AU2001255475A2 publication Critical patent/AU2001255475A2/en
Application granted granted Critical
Publication of AU2001255475B2 publication Critical patent/AU2001255475B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2001255475A 2000-05-01 2001-04-19 Method of reducing side effects of chemotherapy in cancer patients Ceased AU2001255475B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/561,917 US6462017B1 (en) 2000-05-01 2000-05-01 Method of reducing side effects of chemotherapy in cancer patients
US09/561,917 2000-05-01
PCT/US2001/012696 WO2001082949A2 (en) 2000-05-01 2001-04-19 Method of reducing side effects of chemotherapy in cancer patients

Publications (3)

Publication Number Publication Date
AU2001255475A1 AU2001255475A1 (en) 2002-01-31
AU2001255475A2 AU2001255475A2 (en) 2003-03-06
AU2001255475B2 true AU2001255475B2 (en) 2006-01-05

Family

ID=24244042

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001255475A Ceased AU2001255475B2 (en) 2000-05-01 2001-04-19 Method of reducing side effects of chemotherapy in cancer patients
AU5547501A Pending AU5547501A (en) 2000-05-01 2001-04-19 Method of reducing side effects of chemotherapy in cancer patients

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU5547501A Pending AU5547501A (en) 2000-05-01 2001-04-19 Method of reducing side effects of chemotherapy in cancer patients

Country Status (9)

Country Link
US (1) US6462017B1 (cg-RX-API-DMAC7.html)
EP (1) EP1357935B1 (cg-RX-API-DMAC7.html)
JP (1) JP2004501870A (cg-RX-API-DMAC7.html)
CN (1) CN100441221C (cg-RX-API-DMAC7.html)
AT (1) ATE348630T1 (cg-RX-API-DMAC7.html)
AU (2) AU2001255475B2 (cg-RX-API-DMAC7.html)
CA (1) CA2407238C (cg-RX-API-DMAC7.html)
DE (1) DE60125417D1 (cg-RX-API-DMAC7.html)
WO (1) WO2001082949A2 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE554756T1 (de) * 2001-03-14 2012-05-15 Bristol Myers Squibb Co Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
UA77999C2 (en) * 2001-12-10 2007-02-15 Thymosin-alpha 1 for treatment of malignant glioblastoma
KR20050086819A (ko) * 2002-11-25 2005-08-30 시클론 파마수티컬 인코포레이티드 알파 티모신을 사용한 방사능 손상에 대한 보호방법
JP2006213645A (ja) * 2005-02-03 2006-08-17 Hokkaido Univ ゲラニルゲラニルアセトンと抗癌剤とを組み合わせてなる医薬
JP5044150B2 (ja) * 2005-08-05 2012-10-10 Ｔｏｔｏ株式会社 光照射により薬効を消失させる医薬二酸化チタン複合材
US8017129B2 (en) * 2006-06-15 2011-09-13 SciClone Pharmaceuticals International Ltd Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma
US20070292392A1 (en) * 2006-06-15 2007-12-20 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma
US20080253997A1 (en) * 2007-03-27 2008-10-16 Perscitus Biosciences, Llc Compositions and methods for protecting cells from toxic exposures
US20080300166A1 (en) * 2007-06-01 2008-12-04 Sciclone Pharmaceuticals, Inc. Treatment of Melanoma with Alpha Thymosin Peptides
JP2011506467A (ja) * 2007-12-14 2011-03-03 サイクローン・ファーマシューティカルズ・インコーポレイテッド 抗悪性腫瘍性熱ショックアポトーシス活性化因子（ｈｓａａ）と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
CA2753844A1 (en) * 2008-03-05 2009-09-11 Vicus Therapeutics, Llc Compositions and methods for mucositis and oncology therapies
WO2012109106A1 (en) * 2011-02-09 2012-08-16 Sciclone Pharmaceuticals, Inc. Thymosin alpha peptide for preventing, reducing the severity of, and treating infection
US20140322320A1 (en) * 2013-04-24 2014-10-30 Uday Saxena Novel compositions for emesis control in cancer patients undergoing chemotherapy and methods thereof
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
RU2726131C2 (ru) 2015-05-22 2020-07-09 Дмитрий Дмитриевич Генкин Внеклеточная днк в качестве терапевтической мишени при нейродегенерации
CA3001543C (en) * 2015-10-29 2023-06-27 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
CN107137684A (zh) * 2017-05-23 2017-09-08 山西中医学院 一种用于胃肠疾病的药物组合物及其制备方法和用途
FR3074042A1 (fr) 2017-11-29 2019-05-31 Galderma Research & Development Kit pour son utilisation dans la prevention et/ou le traitement des effets secondaires lies a une therapie anticancereuse
EP3740581A4 (en) 2018-01-16 2021-10-27 CLS Therapeutics Limited TREATMENT OF DISEASES BY LIVER EXPRESSION OF AN ENZYME WITH DESOXYRIBONUCLEASE (DNASE) ACTIVITY
CN109820859A (zh) * 2019-04-09 2019-05-31 上海市计划生育科学研究所 醋酸诺美孕酮在制备预防或治疗呕吐或改善恶病质的药物中的应用
IT202300020361A1 (it) 2023-10-03 2025-04-03 Blue Hydrogen Science S R L Nuovi utilizzi di soluzioni acquose ad elevata concentrazione di idrogeno

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US527393A (en) * 1894-10-09 Busy-test for multiple switchboards
US5273963A (en) 1991-03-29 1993-12-28 The George Washington University Compositions and methods for treating small cell and nonsmall cell lung cancers
US5728707A (en) * 1995-07-21 1998-03-17 Constantia Gruppe Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Garachi, E et al., 1995 *
Ishitsuka, H et al., 1984 *
Ohta Y et al., 1985 *
Salvati, F et al., 1996 *
Silecchia, G et al., 1999 *

Also Published As

Publication number Publication date
WO2001082949A9 (en) 2004-04-22
DE60125417D1 (de) 2007-02-01
JP2004501870A (ja) 2004-01-22
WO2001082949A3 (en) 2003-08-28
CN100441221C (zh) 2008-12-10
US6462017B1 (en) 2002-10-08
CA2407238C (en) 2012-03-13
CA2407238A1 (en) 2001-11-08
WO2001082949A2 (en) 2001-11-08
HK1060280A1 (en) 2004-08-06
EP1357935A2 (en) 2003-11-05
CN1529614A (zh) 2004-09-15
AU5547501A (en) 2001-11-12
ATE348630T1 (de) 2007-01-15
EP1357935B1 (en) 2006-12-20

Similar Documents

Publication Publication Date Title
CA2407238C (en) The use of thymosin alpha 1 to reduce the side effects of chemotherapy in cancer patients
AU2001255475A1 (en) Method of reducing side effects of chemotherapy in cancer patients
AU2001255475A2 (en) Method of reducing side effects of chemotherapy in cancer patients
EP3606559B1 (en) Bioorthogonal compositions
US6811788B2 (en) Combinations and methods for treating neoplasms
DE69533069T2 (de) Zusammensetzung zur hemmung von innerer hyperplasie unter verwendung von pdgf antagonisten und heparin
Favalli et al. Modulation of natural killer activity by thymosin alpha 1 and interferon
AU745769B2 (en) Compositions for treating tumors containing shark cartilage extracts and anti-neoplastic agents
WO2018112040A1 (en) Near infrared (nir) photodynamic therapy (pdt) in combination with chemotherapy
MX2010013196A (es) Combinaciones antineoplasticas que contienen hki-272 y vinorelbina.
US20250281511A1 (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
JP5642892B2 (ja) 多形膠芽腫の治療のためのマシテンタンを含有する組み合わせ剤
RU2730998C2 (ru) Композиции форболовых эфиров и способы их применения для лечения или уменьшения продолжительности цитопении
CN117224550B (zh) 一种用于治疗急性髓系白血病的药物组合物
Kasper et al. Recombinant human erythropoietin in combined treatment with granulocyte-or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes
CN101528251B (zh) 用于预防和治疗糖尿病性周围神经病变的含有g-csf的治疗剂
US20060014709A1 (en) Drug or cosmetic
KR102187681B1 (ko) 히알루론산 나노입자를 함유하는 섬유증의 예방 또는 치료용 약학 조성물
HK1060280B (en) Reducing side effects of chemotherapy in cancer patients
CN114129565A (zh) 组蛋白甲基转移酶ezh2抑制剂在促使骨代谢进入高转换以修复骨缺损产品中的应用
TW201408321A (zh) 治療癌症之協同組合
CN116036106A (zh) 一种治疗淋巴水肿的药物运用
US20140309167A1 (en) Combination of active ingredients for the treatment of acute kidney injury
US20260070946A1 (en) Tyr peptide compositions and methods for use
DE69829992T2 (de) Methode zur mobilisierung hematopoietischer stammzellen

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 04 DEC 2002

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired